Safety and immunogenicity of dTpa vaccine administered in pregnancy

Project Details

A phase IV, observer-blind, placebo-controlled and randomised study will be conducted to assess the safety and immunogenicity of dTpa vaccine given during 27-36 weeks of gestation in healthy women aged 18-45 years. We aim to demonstrate that the immunogenicity of a single dose of dTpa vaccine is superior to controls in terms of pertussis antibodies, in the cord blood sample. Safety wil also be evaluated.


Professor Terry Nolan

Dr Kirsten Perrett


National Health and Medical Research Council Career Award


Research Group

Vaccine and Immunisation group research

Faculty Research Themes

Infection and Immunology, Child Health

School Research Themes

Disparities, disadvantage and effective health care

Key Contact

For further information about this research, please contact the research group leader.

MDHS Research library
Explore by researcher, school, project or topic.